AstraZeneca expands Canada R&D work, to add 500 jobs
AstraZeneca will expand its Canada R&D footprint, expanding its center near Toronto and creating a new rare diseases research center there with its Alexion unit, the company said.
The UK drugmaker said the expansion will add 500 jobs. The existing operations there help run many of AstraZeneca’s clinical trials, according to the release. Currently, AstraZeneca has about 1,200 employees in the country, mostly at its hub in the Toronto suburbs.
The R&D hiring runs counter to current trends in biotech, where small companies have announced layoff after layoff in recent months as they run out of funding or studies read out negatively.
The expansion will create a new Alexion, AstraZeneca Rare Disease Development Hub, the drugmaker said.
“Our investment in the AstraZeneca R&D Hub and Alexion Development Hub will play a critical role in the development of new and innovative medicines,” said AstraZeneca Canada president Kiersten Combs.